ADROPIN - POTENTIAL LINK IN CARDIOVASCULAR PROTECTION FOR OBESE MALE TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH LIRAGLUTIDE

The aim of this study was to determine plasma adropin concentration and parameters of insulin resistance in obese male type 2 diabetes mellitus (T2DM) patients before and after 3-month liraglutide treatment. In this interventional study, we enrolled 15 obese male T2DM patients with body mass index (BMI) >35 kg/m(2), uncontrolled disease and HbA(1c) >7.5%, having previously taken taking two oral antidiabetic drugs. We modified their therapy to metformin and liraglutide for the next three months. After three months of liraglutide treatment, we observed significant decrease in body weight (from 111.5 +/- 18.7 kg to 109.2 +/- 17.5 kg, p=0.016) and BMI (from 40.9 +/- 7.3 to 40.1 +/- 7.0 kg/m(2), p=0.021). Plasma adropin concentration increased significantly (p=0.003) compared with baseline. Fasting plasma insulin level decreased from 17.79 +/- 6.53 to 13.38 +/- 3.51 mU/L (p=0.002), fasting plasma glucose level decreased from 8.66 +/- 3.07 to 7.41 +/- 2.21 mmol/L (p=0.004) and HbA(1c) decreased from 7.98 +/- 0.70% to 7.26 +/- 0.36% (p=0.003). Insulin resistance presented as HOMA-IR decreased significantly from 7.30 +/- 5.19 to 4.52 +/- 2.61 (p=0.002). Systolic blood pressure, lipid status, liver and kidney function improved, but not reaching statistical significance. Treating obese male T2DM patients with liraglutide resulted in a significantly higher plasma adropin concentration, significant weight loss and improved parameters of insulin resistance, i.e. decreased fasting plasma insulin, plasma glucose levels and HOMA-IR.